The news of Neogenomics' RaDaR assay obtaining its first pan-cancer commercial coverage by Blue Shield of California is a positive development for the company. This coverage will likely lead to increased adoption of the assay, resulting in higher revenues for Neogenomics. As a result, the stock price is likely to go up in the short term.